Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Techwell Biopharmaceutical Co. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there is 1 pending office action for the company. This action represents the current active engagement with the patent office. For a practitioner, this indicates that the company's immediate biopharmaceutical patent strategy is focused on a single pending application.
The portfolio is being examined by a distinct examiner within a single art unit. This suggests a highly specialized or narrow technical focus for the company's biopharmaceutical filings. D' AMBROSIO, THEA is identified as the busiest examiner for this portfolio. The use of a single art unit means that the prosecution is subject to the specific internal policies and technical expertise of that administrative group.
D' AMBROSIO, THEA is responsible for 1 busiest examiner pending office action. With only a single pending action in total, the prosecution outcome is currently tied to the review of D' AMBROSIO, THEA. Practitioners should monitor the specific requirements of this examiner and the art unit to effectively manage the company's intellectual property and secure favorable results.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006110 | ECHINOCANDIN DRUG IMPURITY, AND PREPARATION AND PURIFICATION METHODS AND USE THEREOF | D' AMBROSIO, THEA | 5d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18006110 | ECHINOCANDIN DRUG IMPURITY, AND PREPARATION AND PURIFICATION METHODS AND USE THEREOF | D' AMBROSIO, THEA | 1654 | §112 | Final Rejection | 5d | Pending | Jan 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial